Larvol Delta - Avenzo-Therapeutics-Announces-Global-License-of-AVZO021-ARTS021-a-Potentially-BestinClass-Clinical-Stage-CDK2-Inhibitor-from-Allorion-Therapeutics

AVZO-103 - Avenzo Therap

http://clinicaltrials.gov/ct2/show/NCT07299747

Dec 24, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next